Novaliq GmbH Receives € 2.3 Million Funding
Summary
With the new funds the company intends to advance its lead projects into clinical development and to strengthen and broaden the technology platform. “We are pleased about the ongoing confidence and support from our investor in order to systematically develop the company with our technology platform”, Bernhard Günther, Managing Director and co-founder of Novaliq says. We see a big potential and numerous applications for the technology platform which we continue to support with this new financing” says Friedrich von Bohlen. NOVALIQ GmbH is a drug delivery company whose goal is to develop innovative pharmaceutical formulations. The patented semifluorinated alkanes (SFAs) can be used in various routes of administration for the transport of drugs or oxygen for therapeutic purposes.